Categories : Endocrine & Metabolic
Product Packaging : 10 / 30 tablets
Product Composition : 5 mg / 500 mg, 10 mg / 500 mg, 10 mg / 850 mg, 10 mg / 1000 mg
Send MessageDapagliflozin & Metformin HCl Extended-Release Tablets represent a modern fixed-dose combination designed for comprehensive management of type 2 diabetes mellitus. This formulation integrates two complementary mechanisms—Dapagliflozin, an SGLT2 inhibitor that promotes urinary glucose excretion, and Metformin HCl, a biguanide that reduces hepatic glucose production and improves insulin sensitivity.
The extended-release (ER) technology of Metformin ensures gradual drug release, enhancing gastrointestinal tolerability and maintaining stable plasma glucose levels throughout the day. This dual-action therapy is widely used in patients requiring improved glycemic control beyond monotherapy, particularly in long-term diabetes and cardiometabolic care programs.
Genliva Wellness LLP, Himatnagar, India, is a leading dapagliflozin metformin ER tablets manufacturer India pharma and combination antidiabetic tablets exporter India, offering high-quality, WHO-GMP compliant formulations for hospitals, endocrinology clinics, pharmacies, and international pharmaceutical markets.
Dapagliflozin & Metformin HCl Extended-Release Tablets combine an SGLT2 inhibitor with an extended-release antidiabetic agent to provide effective blood glucose control in type 2 diabetes management. The formulation supports prolonged therapeutic action and improved metabolic control.
These tablets are commonly used for the treatment of type 2 diabetes mellitus in adults. They help improve blood sugar control along with diet and exercise support.
Dapagliflozin & Metformin HCl Extended-Release Tablets provide dual-action blood sugar control with enhanced patient convenience and long-term diabetes management support.
